Institution Agreement: The Woolmark Performance ChallengeInstitution Agreement • October 7th, 2021
This document sets out the terms for an eligible tertiary education or vocational education provider ('Institution') to register for the Woolmark Performance Challenge (‘Competition’) and includes the Institution Terms Summary and the Terms and Conditions (together, the ‘Agreement').
INSTITUTION AGREEMENT SMLOUVA O ZDRAVOTNICKÉM ZAŘÍZENÍInstitution Agreement • April 13th, 2017
This Institution Agreement (the "Agreement") is made and entered into by and between: Tato Smlouva o zdravotnickém zařízení (dále jen „Smlouva“) se sepisuje a uzavírá mezi:
ContractInstitution Agreement • September 7th, 2020
INSTITUTION AGREEMENTProtocol # XXXXXXXXX This institution agreement (the “Agreement”) is entered into as of the date of last signature hereto (the “””Effective Date”) by and be- tween Idorsia Pharmaceuticals Ltd., having as a place of business Hegenheimermattweg 91, 4123 Allschwil , Switzerland (“Idorsia”), and Fakultni nemocnice Kralovske Vinohrady lo- cated at Srobarova 1150/50, 100 34 Prague 10; Identification number KH/12/00/2020, VAT CZ00064173, cost center 21014 established by decision of the Ministry of Health fo 29.5.2012 file no.: MZDR 17266-III/2012,amending and supplementing the decision of Minister of Health of 25.11.1990 Ref. OP-054- 25.11.90, as amended by the Measure of the Ministry of Health issuee under ref. No.: MZDR 33222/2016 – 2 /OPŘ of 31 May 2016,represented by Prof. MUDr. Petr Arenberger, DrSc. MBA, FCMA, Director of Hospital (the„Institution“) referred to individually herein as a “Party” or collectively as the “Parties”. A. Idorsia is conducting a clinical res
INSTITUTION AGREEMENT ZMLUVA SO ZDRAVOTNÍCKYM ZARIADENÍMInstitution Agreement • April 13th, 2015
Fakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica (F. D. Roosevelt University Hospital and Policlinic Banská Bystrica)
TO THE INSTITUTION AGREEMENTInstitution Agreement • April 28th, 2016
Amendment No. 3 to the Institution Agreement dated 02 August 2010 for the Ponesimod study / AC- 058B202 between ACTELION Pharmaceuticals Ltd Gewerbestrasse 164123 Allschwil Switzerland(hereinafter “ACTELION”) andKrajská zdravotní, a.s. with seat...Institution Agreement • February 4th, 2019
Amendment No. 3 to the Agreement on conducting a clinical study / Dodatek č. 3 ke Smlouvě oprovedení klinické studie This Amendment No. 3 (the “Amendment”) to the Agreement on conducting a clinical study dated 02 August 2010 (the “Agreement”) for the clinical study conducted in accordance with the Protocol AC-058B202 titled: “Multicenter, randomized, double-blind, parallel-group extension to AC-058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20 and 40mg/day ACT- 128800, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis” and following amendments: Amendment No. 1. entered on 29 June 2012 and Amendment No. 2. entered on 16 April 2015 thereto (the “Study”), has been concluded by and between: Tento Dodatek č. 3 (dále jen „Dodatek“) ke ke Smlouvě o provedení klinické studie ze dne 2. srpna 2010 (dále jen „Smlouva“) o klinickém hodnocení prováděném v souladu s Protokolem č. AC-058B202 nazvaným:„Multicentrické, randomizované,
AMENDMENT # 2 TO INSTITUTION AGREEMENTInstitution Agreement • February 13th, 2017
This Amendment (the "Amendment") to the Institution Agreement, dated 13 April 2015 (the “Agreement”), for the clinical study (the “Study”) conducted in accordance with the protocol PIX306 “A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non- Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant” and any amendments thereto (the “Protocol”), is made by and between:
AMENDMENT #3 TO INSTITUTION AGREEMENT DODATOK #3 K ZMLUVE SO ZDRAVOTNÍCKYM ZARIADENÍM This Amendment (the "Amendment") to the Institution Agreement, dated 05 December 2016, in accordance with Addendum No 1 dd 13 May 2029 and Addendum No 2 dd 29...Institution Agreement • August 12th, 2022
This Amendment has been executed in four originals, one for each party. Tento dodatok bol vyhotovený v štyroch origináloch, jeden pre každú zmluvnú stranu. Institution/Zdravotnícke zariadenie: Name/Meno: MUDr. Alexander Mayer, PhD., MPH, MHA, Title/Funkcia: Director/riaditeľ UNB Dated/Dátum: Principal investigator / Hlavný skúšajúci: Name/Meno: prof. MUDr. Peter Valkovič, PhD. Dated/Dátum: PSI: PSI CRO Slovakia s.r.o. Name/Meno:Title/Funkcia: na základe plnej moci / by Power of Attorney Dated/Dátum: Name/Meno:Title/Funkcia: na základe plnej moci / by Power of Attorney Dated/Dátum: Sponsor: executed by PSI based on a Power of Attorney/Zadávateľ: podpisuje PSI na základe plnej moci
INSTITUTION AGREEMENTInstitution Agreement • June 17th, 2020
[Provider Legal Business Name], on behalf of itself and the hospital, ancillary providers, and individual providers to be credentialed under this Agreement hereto (collectively “Provider”), and TriWest Healthcare Alliance Corporation, a Delaware close corporation, (“TriWest”).
ContractInstitution Agreement • August 15th, 2016
Institution Agreement Smlouva o provedení klinického hodnocení se Zdravotnickým zařízením This Institution Agreement (together with Attachment A, the “Agreement”) between AVEO Pharmaceuticals, Inc., a United States Delaware corporation with an office at One Broadway, 14th Floor, Cambridge, MA 02142 USA (“Sponsor” or “AVEO”) represented by PAREXEL International (IRL) Limited, with a registered address at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland, based on Power of Attorney (“PAREXEL”) and(1) Fakultni nemocnice Olomoucwith a place of business at I.P. Pavlova 185/6, 779 00 Olomouc ,Czech Republic, Iden.number: 00098892 , Tax ID number: CZ00098892Represented by: Doc. MUDr. Roman Havlik, Ph.D. (“Institution”) when signed by all parties, is effective as of the date of last signature (the “Effective Date”). Tato smlouva o provedení klinického hodnocení se Zdravotnickým zařízením (dále jen, spolu s přílohou A, "smlouva") se uzavírá mezi AVEO Pharmaceuticals, Inc., společnost registrovan
Institution AgreementInstitution Agreement • March 13th, 2019
This Institution Agreement is made and entered into this 1st day of July, 2019 by and between XAP Corporation (“VENDOR”) and CCC Name (the “Institution”) with respect to the Institution’s participation in an electronic transcript exchange system (the “eTranscript California System”) that is being designed, developed, operated and maintained by VENDOR for Butte-Glenn Community College District (“CLIENT”), acting for the California Community College System (“CCC”).
ContractInstitution Agreement • August 5th, 2022
AMENDMENT 2 TO STATEMENT OF AGREEMENT This Amendment 2 to Statement of Agreement (“Amendment 2”) is made as of the date of last signature, by and between: F. Hoffmann-La Roche Ltd with its registered office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Sponsor”), and PPD Investigator Services LLCwith its registered address at 929 North Front St, Wilmington, NC 28401, USAacting on its behalf and as an independent contractor on behalf of Sponsor (hereinafter referred to as the “PPD”) and Nemocnice Jihlava Vrchlického 59, 586 01 Jihlava, Czech Republic(hereinafter referred to as „ Institution”) andxxxwith his/her offices located at Vrchlického 59, 586 01 Jihlava, Czech Republic (“Investigator”) shall be an amendment to that certain Institution Agreement between Sponsor, PPD, Institution and Investigator dated 20th December 2021, and amendment No 1 dated 05th May 2022 (“Agreement”) for the Clinical trial xxx DODATEK Č. 2 KE SMLOUVĚ Tento Dodatek č. 2 ke Smlouvě (dále jen „Dodatek č.
